Certara (NASDAQ:CERT – Get Rating) had its price target upped by Barclays from $17.00 to $20.00 in a research report sent to investors on Tuesday, The Fly reports. They currently have an overweight rating on the stock.
A number of other brokerages also recently issued reports on CERT. Robert W. Baird downgraded Certara from an outperform rating to a neutral rating and boosted their price target for the company from $17.00 to $19.00 in a report on Wednesday, December 14th. Credit Suisse Group reduced their price target on Certara from $22.00 to $20.00 and set an outperform rating on the stock in a report on Monday, November 14th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Certara currently has an average rating of Moderate Buy and an average price target of $21.86.
Certara Trading Down 1.4 %
NASDAQ CERT opened at $18.46 on Tuesday. Certara has a 1-year low of $10.60 and a 1-year high of $28.62. The company has a current ratio of 3.99, a quick ratio of 3.99 and a debt-to-equity ratio of 0.28. The stock has a 50-day moving average of $16.60 and a 200-day moving average of $16.40. The firm has a market cap of $2.95 billion, a PE ratio of -635.00, a price-to-earnings-growth ratio of 1.25 and a beta of 1.33.
Insiders Place Their Bets
In related news, insider Leif E. Pedersen sold 51,223 shares of the company’s stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $15.55, for a total value of $796,517.65. Following the sale, the insider now owns 175,500 shares in the company, valued at approximately $2,729,025. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, major shareholder Avatar Parent L.P. Eqt sold 29,954,521 shares of the company’s stock in a transaction that occurred on Thursday, December 8th. The stock was sold at an average price of $15.00, for a total value of $449,317,815.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Leif E. Pedersen sold 51,223 shares of the company’s stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $15.55, for a total value of $796,517.65. Following the completion of the sale, the insider now owns 175,500 shares in the company, valued at approximately $2,729,025. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,017,803 shares of company stock worth $450,292,082. Company insiders own 4.02% of the company’s stock.
Institutional Trading of Certara
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. EQT Fund Management S.a r.l. bought a new position in Certara in the 2nd quarter valued at approximately $771,679,000. Clearbridge Investments LLC lifted its position in Certara by 58.7% in the 1st quarter. Clearbridge Investments LLC now owns 3,200,895 shares of the company’s stock valued at $68,755,000 after acquiring an additional 1,183,859 shares in the last quarter. Geneva Capital Management LLC bought a new position in Certara in the 3rd quarter valued at approximately $15,541,000. AEGON ASSET MANAGEMENT UK Plc bought a new position in Certara in the 4th quarter valued at approximately $17,824,000. Finally, Granite Investment Partners LLC bought a new position in Certara in the 2nd quarter valued at approximately $18,944,000. Hedge funds and other institutional investors own 75.45% of the company’s stock.
Certara Company Profile
Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.
- Get a free copy of the StockNews.com research report on Certara (CERT)
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.